Considerations in T Cell Therapy Product Development for B Cell Leukemia and Lymphoma Immunotherapy-Reference-Cited by-同舟云学术

Considerations in T Cell Therapy Product Development for B Cell Leukemia and Lymphoma Immunotherapy

Published:2017-07-31 Issue:4 Volume:12 Page:335-343
ISSN:1558-8211
Container-title:Current Hematologic Malignancy Reports
language:en
Short-container-title:Curr Hematol Malig Rep

Author:

Fesnak Andrew D.,Hanley Patrick J.,Levine Bruce L.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Hematology

Link

http://link.springer.com/article/10.1007/s11899-017-0395-9/fulltext.html

Reference68 articles.

1. Greenberg P, Goodrich J, Riddell S. Adoptive immunotherapy of human cytomegalovirus infection: potential role in protection from disease progression. Transplant Proc. 1991;23(3 Suppl 3):97–101.

2. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science. 1992;257(5067):238–41.

3. Riddell SR, Greenberg PD, Overell RW, Loughran TP, Gilbert MJ, Lupton SD, et al. Phase I study of cellular adoptive immunotherapy using genetically modified CD8+ HIV-specific T cells for HIV seropositive patients undergoing allogeneic bone marrow transplant. The Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Department of Medicine, Division of Oncology. Hum Gene Ther. 1992;3(3):319–38. doi: 10.1089/hum.1992.3.3-319 .

4. Rooney CM, Smith CA, Ng CY, Loftin S, Li C, Krance RA, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet. 1995;345(8941):9–13.

5. Hanley PJ, Bollard CM, Brunstein CG. Adoptive immunotherapy with the use of regulatory T cells and virus-specific T cells derived from cord blood. Cytotherapy. 2015;17(6):749–55. doi: 10.1016/j.jcyt.2014.12.007 .

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enrichment of T-lymphocytes from leukemic blood using inertial microfluidics toward improved chimeric antigen receptor-T cell manufacturing;Cytotherapy;2024-05

2. Gene therapy process change evaluation framework: Transient transfection and stable producer cell line comparison;Biochemical Engineering Journal;2021-12

3. Lentiviral vector bioprocess economics for cell and gene therapy commercialization;Biochemical Engineering Journal;2021-03

4. Validation of a flow cytometry-based method to quantify viable lymphocyte subtypes in fresh and cryopreserved hematopoietic cellular products;Cytotherapy;2021-01

5. Rethinking Cancer Immunotherapy by Embracing and Engineering Complexity;Trends in Biotechnology;2020-10